Gracell Biotechnologies Inc. (GRCL) Analyst Estimates Quarterly - Discounting Cash Flows
GRCL
Gracell Biotechnologies Inc.
GRCL (NASDAQ)
Period Ending: 2024
09-30
2024
06-30
2024
03-30
2023
12-30
2023
09-30
2023
06-30
2023
03-31
2021
12-31
2021
09-30
Number of Analysts 10 10 10 10 10 18 10 10 20
Estimated Revenue
Low 0 0 0 0 0 0 0.146 0.428 0.293
Average 0 0 0 0 0 0 0.125 0.366 0.366
High 0 0 0 0 0 0 0.089 0.26 0.439
Estimated EBITDA
Low 0 0 0 0 0 0 0.088 0.257 -153.8
Average 0 0 0 0 0 0 0.075 0.22 -128.2
High 0 0 0 0 0 0 0.053 0.156 -102.6
Estimated EBIT
Low 0 0 0 0 0 0 0.088 0.257 -157.3
Average 0 0 0 0 0 0 0.075 0.22 -131.1
High 0 0 0 0 0 0 0.053 0.156 -104.9
Estimated Net Income
Low 127.6 111.2 130.5 -20.48 -20.48 -30.63 -28.98 9.94 -155.1
Average 105.2 91.66 107.6 -18.43 -19.12 -25.26 -23.89 8.19 -129.3
High 67.17 58.51 68.7 -17.07 -13.65 -16.12 -15.25 5.23 -103.4
Estimated SGA Expenses
Low None None None None None None None None 34.29
Average None None None None None None None None 42.86
High None None None None None None None None 51.43
Estimated EPS
Low 1.87 1.63 1.91 -0.3 -0.3 -0.449 -0.424 0.146 -0.061
Average 1.54 1.34 1.58 -0.27 -0.28 -0.37 -0.35 0.12 -0.05
High 0.984 0.857 1.01 -0.25 -0.2 -0.236 -0.223 0.077 -0.032
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program